Annexon, Inc.

Unlocking the next generation of complement therapies

South San Francisco, United States · Founded 2016

Employees
1–10
Founded
2016
Business Model
B2B
Last Round
Series ENov 2025
Rounds
6

About

Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines targeting the classical complement pathway via C1q inhibition. Its pipeline addresses autoimmune, neurodegenerative, and ophthalmic disorders, with candidates including ANX005, ANX007, and ANX009 in clinical development. The company was founded in 2011 by Arnon Rosenthal and Ben Barres.

Summary

Annexon, Inc. is a Biopharmaceutical company based in South San Francisco, United States, founded in 2016. Its most recent funding was a Series E round in Nov 2025. Investors include GV, Alta Partners and Bain Capital Life Sciences.

Tech & App Stack

6 technologies & apps tracked

Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Funding History

Sign up to see all 7 rounds

Full funding history, per-round amounts, and investor participation.

Investors

Similar Companies